after mid 2009, page-3

Padd,

Viewing, the bar charts DT approval is a long way off. Similar to Thoratec Heartmate II. The bread & butter is with BTT and markets outside the US.

The current market has forced them to refocus their priorities. This should result in lesser dilution down the track if any further CR’s are raised.

VCR has established markets outside the US but has given them little regard. We now have all of a sudden re-imbursement for Belgium…this has been long in the wind. France and Aus are the next cabs off the rank here.

I wouldn't be surprised if a further CAP is applied for as the emphasis is now revenue driven. And October numbers have shown that.

To get across the line the key is the SPP.